The Association of Radiation Dose With Overall Survival for Patients Treated With Prostate Stereotactic Body Radiation Therapy

Michael R Waters; Neal Andruska; Benjamin W Fischer-Valuck; Temitope Agabalogun; Randall J Brenneman; Hiram Gay; Jeff M Michalski; Brian Baumann

doi:10.7759/cureus.34351

journal article Jan 29, 2023

The Association of Radiation Dose With Overall Survival for Patients Treated With Prostate Stereotactic Body Radiation Therapy

Michael R Waters Neal Andruska

Benjamin W Fischer-Valuck Temitope Agabalogun Randall J Brenneman Hiram Gay Jeff M Michalski Brian Baumann

Cureus · Springer Science and Business Media LLC

View at Publisher Save 10.7759/cureus.34351

Topics

No keywords indexed for this article. Browse by subject →

References

17

[1]

Kishan AU, Dang A, Katz AJ, et al.. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. 2019, 2:e188006. 10.1001/jamanetworkopen.2018.8006 10.1001/jamanetworkopen.2018.8006

[2]

Hegde JV, Collins SP, Fuller DB, et al.. A pooled analysis of biochemical failure in intermediate-risk prostate cancer following definitive stereotactic body radiotherapy (SBRT) or high-dose-rate brachytherapy (HDR-B) monotherapy. Am J Clin Oncol. 2018, 41:502-7. 10.1097/COC.0000000000000311 10.1097/coc.0000000000000311

[3]

Chen LN, Suy S, Uhm S, et al.. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013, 8:58. 10.1186/1748-717X-8-58 10.1186/1748-717x-8-58

[4]

Zietman AL, Bae K, Slater JD, et al.. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010, 28:1106-11. 10.1200/JCO.2009.25.8475 10.1200/jco.2009.25.8475

[5]

Peeters ST, Heemsbergen WD, Koper PC, et al.. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006, 24:1990-6. 10.1200/JCO.2005.05.2530 10.1200/jco.2005.05.2530

[6]

Zelefsky MJ, Kollmeier M, McBride S, et al.. Five-Year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2019, 104:42-9. 10.1016/j.ijrobp.2018.12.045 10.1016/j.ijrobp.2018.12.045

[7]

Morgan SC, Hoffman K, Loblaw DA, et al.. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline. Pract Radiat Oncol. 2018, 8:354-60. 10.1016/j.prro.2018.08.002 10.1016/j.prro.2018.08.002

[8]

Hegemann NS, Guckenberger M, Belka C, Ganswindt U, Manapov F, Li M. Hypofractionated radiotherapy for prostate cancer. Radiat Oncol. 2014, 9:275. 10.1186/s13014-014-0275-6 10.1186/s13014-014-0275-6

[9]

Fowler JF, Toma-Dasu I, Dasu A. Is the α/β ratio for prostate tumours really low and does it vary with the level of risk at diagnosis?. Anticancer Res. 2013, 33:1009-11.

[10]

Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 2005, 44:265-76. 10.1080/02841860410002824 10.1080/02841860410002824

[11]

Draulans C, van der Heide UA, Haustermans K, et al.. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol. 2020, 147:92-8. 10.1016/j.radonc.2020.03.015 10.1016/j.radonc.2020.03.015

[12]

Mohler JL, Antonarakis ES, Armstrong AJ, et al.. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019, 17:479-505. 10.6004/jnccn.2019.0023 10.6004/jnccn.2019.0023

[13]

Constructing Inverse Probability Weights for Marginal Structural Models

S. R. Cole, M. A. Hernan

American Journal of Epidemiology 2008 10.1093/aje/kwn164

[14]

Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015, 34:3661-79. 10.1002/sim.6607 10.1002/sim.6607

[15]

Andruska N, Fischer-Valuck BW, Mahapatra L, et al.. Association between surgical margins larger than 1 cm and overall survival in patients with Merkel cell carcinoma. JAMA Dermatol. 2021, 157:540-8. 10.1001/jamadermatol.2021.0247 10.1001/jamadermatol.2021.0247

[16]

Jackson WC, Silva J, Hartman HE, et al.. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys. 2019, 104:778-89. 10.1016/j.ijrobp.2019.03.051 10.1016/j.ijrobp.2019.03.051

[17]

Widmark A, Gunnlaugsson A, Beckman L, et al.. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019, 394:385-395. 10.1016/S0140-6736(19)31131-6 10.1016/s0140-6736(19)31131-6

Metrics

0

Citations

17

References

Details

Published: Jan 29, 2023

Authors

Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO, USA

B

Benjamin W Fischer-Valuck

Cite This Article

Michael R Waters, Neal Andruska, Benjamin W Fischer-Valuck, et al. (2023). The Association of Radiation Dose With Overall Survival for Patients Treated With Prostate Stereotactic Body Radiation Therapy. Cureus. https://doi.org/10.7759/cureus.34351

The Association of Radiation Dose With Overall Survival for Patients Treated With Prostate Stereotactic Body Radiation Therapy

You May Also Like